01 — At a Glance
The Plastic Company That Accidentally Became a Pharma Device Superpower
- 52-Week High / Low₹2,800 / ₹1,373
- Q3 FY26 Revenue₹251 Cr
- Q3 FY26 PAT₹37 Cr
- Q3 EPS (₹)₹7.89
- Annualised EPS (Q3×4)₹31.56
- Book Value₹123
- Price to Book15.8x
- Debt / Equity0.3x
- 9M FY26 Revenue₹754 Cr
- 9M FY26 PAT₹130 Cr
Auditor’s Opening Note: Shaily closed Q3 FY26 with ₹251 crore revenue (+27% YoY), ₹37 crore PAT (+48% YoY), and a ROCE of 38.4%. But here’s the kicker: healthcare revenue is now 42% of the business (was 17% a year ago), and management just unveiled a ₹300+ crore expansion in Abu Dhabi to manufacture GLP-1 auto-injectors. The stock is at P/E 62.6x. Do the math — this is either the greatest bet on pharma device outsourcing ever made, or an expensive gamble on automation risk. Possibly both.
02 — Introduction
When Plastic Moulding Became Pharmaceutical Roulette
Shaily Engineering Plastics Limited (SEPL) was founded in 1980 as a quiet, competent manufacturer of injection-moulded plastic components. Unremarkable. Dependable. The kind of company that supplies plastic parts to FMCG, home furnishing, and automotive — sectors where competition is fierce and margins are sad. For 40+ years, they were content to be exactly that.
Then the GLP-1 revolution happened. Ozempic, Mounjaro, and their copycat cousins created a global shortage of pen injectors. Suddenly, companies that could manufacture precision auto-injector devices with pharmaceutical-grade accuracy and scale became invaluable. Shaily had the machines, the talent, and the certifications (ISO 13485, MDSAP, cleanrooms with ISO Class 8 standards). They pivoted hard.
Q3 FY26 results just landed. The numbers tell the story: healthcare revenue jumped 139% YoY to ₹104 crore, while consumer (the legacy cash cow) cratered 13% YoY to ₹123 crore. In nine months, Shaily has generated 9M revenue of ₹754 crore with PAT jumping 101% to ₹130 crore. The company is now valued at ₹8,894 crore. Three years ago, it was worth ₹500 crore. That’s not luck. That’s a very deliberate, very ambitious pivot toward a market with existential supply constraints. And management just went nuclear on that bet by announcing a new facility in Abu Dhabi for 75 million pens a year. Let’s break down what’s happening, what could go right, and what could absolutely explode.
Concall Note (Feb 2026): “We expect to be 50-60% contracted on Abu Dhabi capacity before we even break ground. Take-or-pay contracts with annual minimums. Some customers pre-pay 20-40%.” — Shaily Management. Translation: they’ve already won the game; they’re just building the stadium to prove it.
03 — Business Model: From Generic Plastic to Precision Pharma
From 40-Year-Old Moulding Factory to GLP-1 Supply Chain Kingpin
Shaily operates in three business segments. Consumer, Healthcare, and Industrial. But let’s be real — Consumer is slowly becoming vestigial.
Consumer Segment (49% of 9M FY26 revenue): Home furnishings, FMCG packaging, LED lights, and toys (via a Spin Master partnership that sounds fun on paper but contributes nothing to investor returns). They manufacture plastic injection-moulded parts at scale. This is a commoditised, low-margin business. Margins in FY25 were ~15%. Revenue declined 1% YoY in 9M FY26. It’s a legacy business that management is quietly deprioritizing, which is exactly what shareholders want.
Healthcare Segment (37% of 9M FY26 revenue): Now the crown jewel. They manufacture pen injectors, auto-injectors, wearable injectors, and platform devices for pharmaceutical companies. The segment grew 158% YoY in 9M FY26 (₹280 cr). They have signed contracts with pharma firms for GLP-1 supply, notably including a 4-year, ₹423-crore contract announced in February 2026 with a “large domestic pharma.” They’ve already begun supplying GLP-1 devices for Canada, Brazil, India, Middle East, and Turkey. The capacity is constrained, qualification is grueling, but the demand is relentless. Management stated customers are “breathing down our necks for supply.” That doesn’t sound like typical business pressure — that sounds like addiction-level desperation.
Industrial Segment (9% of 9M FY26 revenue): Carbon steel, automotive components, appliances, and engineering parts. Growing +36% YoY. Small, but present. Semiconductor casing opportunity is real but dependent on fab ramp-up in India (which they say happens in ~12 months). Immaterial for now.
Healthcare Mix42%Q3 FY26 Revenue
Consumer Mix49%9M FY26 Revenue
Industrial Mix9%9M FY26 Revenue
The Real Moat: Shaily operates 7 manufacturing facilities across Gujarat with ISO Class 8 cleanroom capabilities. They hold MDSAP certification (global pharma device standards), three-star export house status, and have been furnishing OEMs for 40+ years. Competitors like Gulf Oil, Kingfa, Supreme Industries can make plastic. They can’t make pharmaceutical-grade plastic injectors at scale without losing their minds to qualification risk. Shaily already has the infrastructure and the certifications. That’s worth billions in a supply-constrained market.
💬 Here’s the real question: if demand is so tight that customers are “breathing down their necks,” why are they building capacity in Abu Dhabi instead of tripling capacity in India? Read the next section — the answer is candidly unexpected.
04 — Financials Overview
Q3 FY26: The Numbers (Quarterly Results)
Continue reading with a premium membership.
